US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Indigo Acquisition Corporation (INAC) 銘柄情報

Indigo Acquisition Corporation (INAC)

10.2484

0.0084

(0.08%)

終了 7月5日 5:00AM

10.2484

0.00

(0.00%)

取引時間後: 6:23AM

Indigo Acquisition Corporation (INAC) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

10.2484

( 0.08% )

買値

3.94

売値

16.60

出来高

18,970

10.24 日の範囲 10.27

9.93 52 週間の範囲 10.27

時価総額

前日終値

10.24

始値

10.24

時刻

最終取引時間

財務取引量

US$ 194,792

VWAP

10.2684

平均取引量 (3 か月)

US$ 12,007

発行済株式数

14,755,000

配当利回り

PER

42.52

1 株当たり利益 (EPS)

0.24

歳入

-

純利益

2.83M

Indigo Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Miami, Florida. Indigo Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Miami, Florida.

セクター

-

業界

-

ウェブサイト

www.indigoacquisitioncorp.com

本社

Miami, United States

設立

2026

Indigo Acquisition Corporation is listed in the sector of the ナスダック市場 with ticker INAC. The last closing price for Indigo Acquisition was US$10.24. Over the last year, Indigo Acquisition shares have traded in a share price range of US$ 9.93 to US$ 10.27.

Indigo Acquisition currently has 14,755,000 shares in issue. The market capitalisation of Indigo Acquisition is US$151.22 million. Indigo Acquisition has a price to earnings ratio (PE ratio) of 42.52.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.0284	0.277886497065	10.22	10.27	10.22	5990	10.2499212	CS
4	0.0284	0.277886497065	10.22	10.27	10.15	16864	10.23728365	CS
12	0.1084	1.06903353057	10.14	10.27	10.14	8480	10.21641059	CS
26	0.2084	2.07569721116	10.04	10.27	10.04	11843	10.14751013	CS
52	0.3084	3.10261569416	9.94	10.27	9.93	19477	10.03400259	CS
156	0.3084	3.10261569416	9.94	10.27	9.93	19477	10.03400259	CS
260	0.3084	3.10261569416	9.94	10.27	9.93	19477	10.03400259	CS

INAC - Frequently Asked Questions (FAQ)

What is the current Indigo Acquisition Corporation share price?

The current share price of Indigo Acquisition Corporation is US$ 10.2484

How many Indigo Acquisition Corporation shares are in issue?

Indigo Acquisition Corporation has 14,755,000 shares in issue

What is the market cap of Indigo Acquisition Corporation?

The market capitalisation of Indigo Acquisition Corporation is USD 151.22M

What is the 1 year trading range for Indigo Acquisition Corporation share price?

Indigo Acquisition Corporation has traded in the range of US$ 9.93 to US$ 10.27 during the past year

What is the PE ratio of Indigo Acquisition Corporation?

The price to earnings ratio of Indigo Acquisition Corporation is 42.52

What is the registered address of Indigo Acquisition Corporation?

The registered address for Indigo Acquisition Corporation is 3250 Mary Street, Miami, Florida, 33131

What is the Indigo Acquisition Corporation website address?

The website address for Indigo Acquisition Corporation is www.indigoacquisitioncorp.com

TightCoil

TightCoil 10分前

Glen Bradford - Looks Like Trump Team Simply Maximizing Frannie IPO (OTCMKTS:FNMAS)
Seeking Alpha - 17 hours ago

TechBullion
Could Pepeto Be the Best Crypto Presale to Buy as
Fannie Mae Opens the Door to Crypto Mortgages?
5 hours ago

weenphan

weenphan 17分前

https://www.otcmarkets.com/stock/CVALF/profile

Kool Aid Man

Kool Aid Man 18分前

Measly $44k left in the gas tank

40 million shares left to issue x .0011

No one goes public if they intend to self finance operations. The whole point is to print and sell shares to raise money...not to reward old bag holders who were conned by Miro years ago. Why split

jondoeuk

jondoeuk 19分前

Calling this the "gold standard" doesn't answer all the underlying concerns. This isn't a refinement of the original external-control analysis either. It uses a completely different set of external comparator trials. That means the reported survival estimate depends on which external patients are se

manibiotech

manibiotech 21分前

Yes we all know that . The previous external control arm patients were “external” , and the one’s in new PSM analysis are also different ‘external’ patients with patient level propensity matching ( so even better controls) and show even better treatment benefit . So again, what is the point you are

Naught

Naught 22分前

Should we expect some notices from. PAC in the very near term then...?

weenphan

weenphan 22分前

I posted on the PCHM board for over a decade. I bought PCHM as low as .0013 and sold stock as high as $5 plus. It was a once in a lifetime percentage gainer. My aliases were LMLYP, Rosesarefree and GeneandDean, which all are references to a band Ween. I'm weenphan on this board.

newflow

newflow 22分前

Ron, Dissolved vs Extinct
No Altaba distributed immediately before dissolution, can you find any company distributing value to equity holders after its complete dissolution long-form or regular Dissolution.
Gemini's Response:
It is important to clarify a key point about Delaware

DA88

Can someone explain who this guy is and why his perspective matters? Love that he is positive, but he doesn’t look like he is anything more than a shareholder.

PickStocks

PickStocks 25分前

Yes….but we do not have anything to do with Paladin. So it means nothing which is easily verified by a simple phone call….

jondoeuk

jondoeuk 30分前

Whether this particular analysis has been submitted is something nobody outside NWBO and the MHRA knows.

jondoeuk

jondoeuk 32分前

This is not simply a refinement of the published JAMA Oncology analysis. It's a different external-control analysis built from a different pool of comparator trials. The fact they constructed a propensity-score matched analysis using individual patient data from AVAGLIO, CENTRIC, and CORE, means the

ihorchu

ihorchu 34分前

A fantastic day to remember! Since no humidity here, heat is very tolerable.

jondoeuk

jondoeuk 39分前

'While encouraging, our clinical findings must be interpreted with caution. Even though this was a randomized clinical trial (randomization software assigned patients to TLR agonist/placebo groups), the small number of patients enrolled contributed to an imbalance in patient selection between the tr

kevindenver

kevindenver 39分前

Nowhere in the interview was "Blarcamesine" mentioned. There was a snippet towards the end where autophagy is mentioned.

Maybe you hallucinated that this interview was related to blarcamesine?

A transcript of the interview can be found here:
https://podcasts.hap

TightCoil

TightCoil 47分前

Yes, next week is the week we FLY

TightCoil

TightCoil 49分前

FNMA/FMCC
On Schwab Now
FNMA ask $7.33
FMCC ask $9.31
Load up Early
Remember:Again- Will you be quick enough to grab some of these shares once one or more current "announcements in the making," are made? Will you be quicker than the big gun buying stampede when eve

JonDoe1

JonDoe1 50分前

He's extra angry today. Possibly hit the 4th of July drinks a little early. That poor keyboard.

kenjiroo

kenjiroo 51分前

Happy 4th longs !!!

US Market News

US Market News 51分前

SK Telecom Pursues 15GW AI Data Center Buildout, Aiming to Become Asia's AI Infrastructure HubJuly 4, 2026 8:29 PM
PR Newswire (US) Ulsan AI Data Center to expand to GW scale; 5GW to be activated in stages from 2029, reaching 15GW in to

long_haul

long_haul 51分前

I like this guy a lot ! Next week is going to be fire

JonDoe1

JonDoe1 51分前

STOP RESPONDING TO MY POSTS

It's a public forum.

garyhalvo

garyhalvo 54分前

IMO, September 13th will probably end because I believe that all of those dates that were posted with the court has come and went, so I don’t see anything in the way. How long will it be till we get our money after that, I think by the end of September.

Indigo Acquisition

Wartsila Oyj Abp

Keurig Dr Pepper

PANATLANTICA PN

Next Science (PK)

Cognizant Technology Sol...

Comfort Systems USA

Bourque Industries (EM)

Switzer Asset Management

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。